Dr. Seymour on Investigational BTK Inhibitors in CLL

Video

Erlene Seymour, MD, discusses investigational BTK inhibitors in chronic lymphocytic leukemia.

Erlene Seymour, MD, an assistant clinical professor at Wayne State University School of Medicine and a hematologist/oncologist at Barbara Ann Karmanos Cancer Institute, discusses investigational BTK inhibitors in chronic lymphocytic leukemia (CLL).

Currently, BTK inhibitors, such as tirabrutinib, are being evaluated for patients with CLL, says Seymour. Additionally, BTK inhibitors, such as LOXO-305 and vecabrutinib, have the potential to overcome BTK resistance mutations, Seymour explains.

As more agents are introduced to the landscape, a similar challenge regarding treatment selection may be faced with BTK inhibitors as is the case in chronic myeloid leukemia with TKIs, Seymour says. As these drugs continue to advance through the CLL pipeline, the field can better assess the toxicities associated with these agents to inform treatment selection for patients with CLL, concludes Seymour.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center